• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients.

作者信息

Albanese J, Martin C, Lacarelle B, Saux P, Durand A, Gouin F

机构信息

Departement d'Anesthesie, Hôpital Nord, Marseille, France.

出版信息

Anesthesiology. 1990 Aug;73(2):214-7. doi: 10.1097/00000542-199008000-00004.

DOI:10.1097/00000542-199008000-00004
PMID:2382846
Abstract

The pharmacokinetics of propofol were determined in nine patients (seven men, two women, (mean +/- SD) 55.8 +/- 21.2 yr, 65.2 +/- 8 kg) requiring prolonged mechanical ventilation of their lungs. After an initial dose of 1-3 mg/kg, propofol was administered iv at 3 mg/kg/h for 72 h. Arterial blood samples were collected at selected times during and up to 72 h after infusion. Propofol whole blood concentrations were determined by high-performance liquid chromatography with fluorescence detection. Individual pharmacokinetic parameters were estimated by noncompartmental analysis. Derived pharmacokinetic parameters showed a long terminal phase (T1/2 = 1878 +/- 672 min), a large volume of distribution at steady state (Vdss = 1666 +/- 756 l), and a high total body clearance (Cl = 1.57 +/- 0.56 l/min). While the propofol terminal elimination half-life is longer than that previously reported, emergence from sedation after prolonged administration will be governed by both redistribution mechanisms arising from the large distribution volumes and elimination from the body.

摘要

相似文献

1
Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients.
Anesthesiology. 1990 Aug;73(2):214-7. doi: 10.1097/00000542-199008000-00004.
2
Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients.丙泊酚/阿芬太尼输注用于ICU患者镇静的药代动力学和药效学
Intensive Care Med. 1995 Dec;21(12):981-8. doi: 10.1007/BF01700659.
3
Pharmacokinetics of propofol during and after long-term continuous infusion for maintenance of sedation in ICU patients.丙泊酚在重症监护病房患者长期持续输注维持镇静期间及之后的药代动力学
Br J Anaesth. 1992 May;68(5):486-91. doi: 10.1093/bja/68.5.486.
4
Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.丙泊酚用于重症患者长期镇静的群体药代动力学和药效学建模:丙泊酚6%与丙泊酚1%的比较
Clin Pharmacol Ther. 2002 Dec;72(6):670-84. doi: 10.1067/mcp.2002.129500.
5
Pharmacokinetics of propofol infusions in critically ill neonates, infants, and children in an intensive care unit.重症监护病房中危重新生儿、婴儿及儿童丙泊酚输注的药代动力学
Anesthesiology. 2002 Dec;97(6):1393-400. doi: 10.1097/00000542-200212000-00010.
6
Pharmacokinetics of propofol when given by intravenous infusion.静脉输注丙泊酚的药代动力学。
Br J Clin Pharmacol. 1990 Jul;30(1):144-8. doi: 10.1111/j.1365-2125.1990.tb03755.x.
7
Plasma concentration for optimal sedation and total body clearance of propofol in patients after esophagectomy.食管癌切除术后患者丙泊酚达到最佳镇静效果时的血浆浓度及全身清除率。
J Anesth. 2005;19(1):88-90. doi: 10.1007/s00540-004-0280-2.
8
Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model.基于整合药代动力学-药效学模型的重症监护病房镇静丙泊酚给药方案。
Anesthesiology. 2001 Aug;95(2):324-33. doi: 10.1097/00000542-200108000-00011.
9
Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients.重症监护病房患者长期输注舒芬太尼镇静的药代动力学
Intensive Care Med. 2003 Nov;29(11):1916-20. doi: 10.1007/s00134-003-1920-y. Epub 2003 Aug 16.
10
Pharmacokinetics of propofol administered by infusion in dogs undergoing surgery.
Br J Anaesth. 1993 May;70(5):546-51. doi: 10.1093/bja/70.5.546.

引用本文的文献

1
Pharmacokinetics and exposure-safety relationship of ciprofol for sedation in mechanically ventilated patients in the intensive care unit.在重症监护病房中,机械通气患者镇静用西普罗的药代动力学和暴露-安全性关系。
CPT Pharmacometrics Syst Pharmacol. 2024 May;13(5):823-836. doi: 10.1002/psp4.13121. Epub 2024 Mar 5.
2
Propofol directly binds to and inhibits TLR7.异丙酚直接与 TLR7 结合并抑制 TLR7。
FASEB J. 2022 Aug;36(8):e22481. doi: 10.1096/fj.202200312R.
3
Sedation Effects Produced by a Ciprofol Initial Infusion or Bolus Dose Followed by Continuous Maintenance Infusion in Healthy Subjects: A Phase 1 Trial.
健康受试者中,采用 Ciprofol 起始输注或推注剂量,随后持续输注维持剂量产生的镇静作用:一项 1 期试验。
Adv Ther. 2021 Nov;38(11):5484-5500. doi: 10.1007/s12325-021-01914-4. Epub 2021 Sep 24.
4
Effects of propofol on the proliferation and migration of liver cancer cells.丙泊酚对肝癌细胞增殖和迁移的影响。
Exp Ther Med. 2021 Jul;22(1):733. doi: 10.3892/etm.2021.10165. Epub 2021 May 9.
5
Volatile Anesthetic Sevoflurane Attenuates Toll-Like Receptor 1/2 Activation.挥发性麻醉剂七氟醚可减弱 Toll 样受体 1/2 的激活。
Anesth Analg. 2020 Aug;131(2):631-639. doi: 10.1213/ANE.0000000000004741.
6
Intravenous anesthetic propofol binds to 5-lipoxygenase and attenuates leukotriene B production.静脉麻醉药丙泊酚与5-脂氧合酶结合并减弱白三烯B的产生。
FASEB J. 2017 Apr;31(4):1584-1594. doi: 10.1096/fj.201601095R. Epub 2017 Jan 9.
7
Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery.丙泊酚在接受大型肺部手术的癌症患者中的药代动力学和药效学。
J Pharmacokinet Pharmacodyn. 2015 Apr;42(2):111-22. doi: 10.1007/s10928-015-9404-6. Epub 2015 Jan 28.
8
[Brain death diagnosis after sedation with propofol or sufentanil. Recommendations for the usage of toxicological analytics].[丙泊酚或舒芬太尼镇静后脑死亡的诊断。毒理学分析的使用建议]
Med Klin Intensivmed Notfmed. 2015 Apr;110(2):145-9. doi: 10.1007/s00063-014-0416-6. Epub 2014 Sep 26.
9
Propofol shares the binding site with isoflurane and sevoflurane on leukocyte function-associated antigen-1.丙泊酚与异氟醚和七氟醚在白细胞功能相关抗原-1上共享结合位点。
Anesth Analg. 2013 Oct;117(4):803-811. doi: 10.1213/ANE.0b013e3182a00ae0. Epub 2013 Aug 19.
10
Volatile anesthetics, not intravenous anesthetic propofol bind to and attenuate the activation of platelet receptor integrin αIIbβ3.挥发性麻醉剂,而非静脉麻醉药异丙酚,与血小板受体整合素 αIIbβ3 结合并减弱其激活。
PLoS One. 2013;8(4):e60415. doi: 10.1371/journal.pone.0060415. Epub 2013 Apr 3.